| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst Sumant Kulkarni maintains Mind Medicine (NASDAQ:MNMD) with a Buy and raises the price target from ...
RBC Capital analyst Brian Abrahams maintains Mind Medicine (NASDAQ:MNMD) with a Outperform and lowers the price target from ...
Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.5...
Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid ...
https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-sugge...
Needham analyst Ami Fadia initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Buy rating and announces Price Target of ...